Contact:
|
Trinity Biotech plc
|
Lytham Partners, LLC
|
John Gillard
|
Joe Diaz
|
|
(353)-1-2769800
|
(1)-602-889-9700
|
|
E-mail: investorrelations@trinitybiotech.com
|
2020
Quarter 1
|
2021
Quarter 1
|
Increase/
(decrease)
|
||||||||||
US$’000
|
US$’000
|
%
|
||||||||||
Point-of-Care
|
3,335
|
1,888
|
(43.4
|
)%
|
||||||||
Clinical Laboratory
|
17,842
|
23,706
|
32.9
|
%
|
||||||||
Total
|
21,177
|
25,594
|
20.9
|
%
|
$m
|
|
Operating Profit
|
3.1
|
Depreciation
|
0.6
|
Amortisation
|
0.2
|
Share Option Expense
|
0.4
|
EBITDASO
|
4.3
|
(US$000’s except share data)
|
Three Months
Ended
Mar 31,
2021
(unaudited)
|
Three Months
Ended
Mar 31,
2020
(unaudited)
|
||||||
Revenues
|
25,594
|
21,177
|
||||||
Cost of sales
|
(14,681
|
)
|
(11,901
|
)
|
||||
Gross profit
|
10,913
|
9,276
|
||||||
Gross profit %
|
42.6
|
%
|
43.8
|
%
|
||||
Other operating income
|
1
|
14
|
||||||
Research and development expenses
|
(1,437
|
)
|
(1,378
|
)
|
||||
Selling, general and administrative expenses
|
(6,019
|
)
|
(6,085
|
)
|
||||
Indirect share based payments
|
(380
|
)
|
(134
|
)
|
||||
Operating profit
|
3,078
|
1,693
|
||||||
Financial income
|
1
|
31
|
||||||
Financial expenses
|
(1,210
|
)
|
(1,232
|
)
|
||||
Net financing expense
|
(1,209
|
)
|
(1,201
|
)
|
||||
Profit before tax, once-off and non-cash items
|
1,869
|
492
|
||||||
Income tax expense
|
(105
|
)
|
(129
|
)
|
||||
Profit after tax before once-off and non-cash items
|
1,764
|
363
|
||||||
Non-cash financial expense
|
(162
|
)
|
(160
|
)
|
||||
Once-off items – closure costs
|
-
|
(2,425
|
)
|
|||||
Profit/(loss) after tax
|
1,602
|
(2,222
|
)
|
|||||
Earnings/(loss) per ADR (US cents)
|
7.7
|
(10.6
|
)
|
|||||
Earnings per ADR (US cents)**
|
8.4
|
1.7
|
||||||
Diluted earnings/(loss) per ADR (US cents)
|
10.1
|
*
|
(4.2
|
)*
|
||||
Diluted earnings per ADR (US cents)**
|
10.1
|
*
|
5.3
|
*
|
||||
Weighted average no. of ADRs used in computing basic earnings per ADR
|
20,901,703
|
20,901,703
|
||||||
Weighted average no. of ADRs used in computing diluted earnings per ADR
|
27,222,372
|
25,467,516
|
Mar 31,
2021
US$ ‘000
(unaudited)
|
Dec 31,
2020
US$ ‘000
(unaudited)
|
|||||||
ASSETS
|
||||||||
Non-current assets
|
||||||||
Property, plant and equipment
|
8,648
|
8,547
|
||||||
Goodwill and intangible assets
|
35,200
|
33,860
|
||||||
Deferred tax assets
|
4,205
|
4,185
|
||||||
Other assets
|
315
|
355
|
||||||
Total non-current assets
|
48,368
|
46,947
|
||||||
Current assets
|
||||||||
Inventories
|
37,582
|
30,219
|
||||||
Trade and other receivables
|
14,864
|
22,668
|
||||||
Income tax receivable
|
2,888
|
3,086
|
||||||
Cash and cash equivalents
|
32,277
|
27,327
|
||||||
Total current assets
|
87,611
|
83,300
|
||||||
TOTAL ASSETS
|
135,979
|
130,247
|
||||||
EQUITY AND LIABILITIES
|
||||||||
Equity attributable to the equity holders of the parent
|
||||||||
Share capital
|
1,213
|
1,213
|
||||||
Share premium
|
16,187
|
16,187
|
||||||
Treasury shares
|
(24,922
|
)
|
(24,922
|
)
|
||||
Accumulated surplus
|
12,561
|
10,573
|
||||||
Translation reserve
|
(5,189
|
)
|
(5,293
|
)
|
||||
Other reserves
|
23
|
23
|
||||||
Total deficit
|
(127
|
)
|
(2,219
|
)
|
||||
Current liabilities
|
||||||||
Income tax payable
|
389
|
154
|
||||||
Trade and other payables
|
30,881
|
26,488
|
||||||
Provisions
|
376
|
416
|
||||||
Total current liabilities
|
31,646
|
27,058
|
||||||
Non-current liabilities
|
||||||||
Exchangeable senior note payable
|
84,045
|
83,884
|
||||||
Other payables
|
15,625
|
16,619
|
||||||
Deferred tax liabilities
|
4,790
|
4,905
|
||||||
Total non-current liabilities
|
104,460
|
105,408
|
||||||
TOTAL LIABILITIES
|
136,106
|
132,466
|
||||||
TOTAL EQUITY AND LIABILITIES
|
135,979
|
130,247
|
(US$000’s)
|
Three Months
Ended
Mar 31,
2021
(unaudited)
|
Three Months
Ended
Mar 31,
2020
(unaudited)
|
||||||
Cash and cash equivalents at beginning of period
|
27,327
|
16,400
|
||||||
Operating cash flows before changes in working capital
|
4,063
|
2,467
|
||||||
Changes in working capital
|
1,830
|
(1,396
|
)
|
|||||
Cash generated from operations
|
5,893
|
1,071
|
||||||
Net interest and income taxes received
|
190
|
431
|
||||||
Capital expenditure and financing (net)
|
(2,196
|
)
|
(2,756
|
)
|
||||
Payments for leases (IFRS 16)
|
(701
|
)
|
(790
|
)
|
||||
Free cash flow
|
3,186
|
(2,044
|
)
|
|||||
Payment of HIV/2 license fee
|
-
|
(1,112
|
)
|
|||||
Proceeds received under Paycheck Protection Program
|
1,764
|
-
|
||||||
Cash and cash equivalents at end of period
|
32,277
|
13,244
|